Author: Anna Smith

Exonate fundraises £1.5 million

Exonate has successfully fundraised £1.5 million to accelerate development of its lead product – an eye drop treatment for retinal neovascular diseases.

Sanofi and MyoKardia end heart disease drug collaboration

Bringing an end to a four-year partnership, Sanofi has terminated its agreement with MyoKardia to jointly develop small-molecule therapeutics, targeting genetic mutations associated with certain heart diseases.

One in 20 GP appointments missed, costing £216m

NHS England is urging patients to cancel appointments rather than just not show up, after news emerged that more than 15 million general practice appointments are being wasted each year because patients do not turn up and fail to warn surgeries in advance.

Pfizer, Merck to terminate Phase III Bavencio study

Pfizer and Merck KGaA have announced that they will be terminating the Phase III JAVELIN Ovarian 100 study of Bavencio, as the data did not support the study’s initial hypothesis.

NHS England to fund Actelion’s Uptravi

Actelion Pharmaceuticals has announced that NHS patients in England, who have the rare, incurable and devastating disease pulmonary arterial hypertension (PAH), can now be treated with Uptravi.